Taurine is a sulfur-containing amino acid found in high concentrations in heart, skeletal muscle, brain and retina. It is synthesised endogenously and present in meat, fish and shellfish; strict vegans have lower circulating levels. Taurine has genuine physiological roles (bile acid conjugation, osmoregulation, calcium handling, antioxidant defence), but human outcome data supporting it as a longevity or performance supplement are limited.
Taurine is safe and cheap, with a small but real performance signal and a plausible role in cardiovascular and glycemic support in some patient populations. The 2023 mouse 'lifespan' headline drove a wave of marketing that outruns the human evidence — long-term outcome trials in humans do not yet exist. Reasonable to try at 1–3 g/day; do not expect dramatic effects.
Each row grades the claimed effect by strength of human evidence, not mechanism or marketing.
Recognised as conditionally essential and physiologically important; used clinically in Japan as a heart-failure adjunct. Not a mainstream recommendation for healthy adults in most Western guidelines.
Heavily promoted after the 2023 mouse study as an anti-aging / longevity compound. Marketing has moved well ahead of human outcome evidence.
A placebo-controlled RCT in healthy older adults measuring clinical outcomes (cardiovascular events, frailty, mortality) over multiple years does not yet exist. Current recommendations rest on animal data plus small patient-population trials.
Dietary taurine comes mainly from meat and seafood — strict vegans and vegetarians have measurably lower circulating taurine. Supplementation may matter more for this group.
Taurine is safe at 1–3 g/day in chronic use and has been used at up to 6 g/day in heart-failure trials without serious adverse effects.
Energy-drink doses (~1 g per can) combined with caffeine are the main context in which adverse effects have been reported, largely attributable to caffeine and stimulant load rather than taurine itself.
The widely cited 2023 Science paper by Singh et al. demonstrated lifespan extension in mice and frailty-related improvements in monkeys, plus observational decline of taurine with age in humans — it is not a human RCT.
Taurine does not produce acute stimulant effects on its own. It is not the source of energy-drink buzz.
Mechanism is not outcome. Each mechanism is labelled by how far it has been validated in humans.
Taurine regulates cell volume, stabilises membranes, and modulates calcium handling in cardiac and skeletal muscle, which underlies its role in cardiac contractility.
Taurine is conjugated to bile acids (tauro-conjugates), affecting fat digestion and enterohepatic signalling. Relevant to its role in lipid metabolism.
Taurine reacts with hypochlorous acid to form taurine chloramine, modulating inflammatory responses. Plausible contributor to observed cardiometabolic effects, though direct human outcome evidence is limited.
Rodent and monkey data suggest taurine supports mitochondrial quality control and delays frailty markers with age. Human translation is hypothesised but unproven.
Well tolerated across the doses studied. A 2019 EFSA review considered intakes up to ~6 g/day safe in healthy adults.
This page is educational and not medical advice. Taurine as a heart-failure adjunct, or in people with bipolar disorder, hypertension, diabetes, or pregnancy considerations, should be discussed with a clinician.
A small, curated set — not a literature dump. Each reference comes with a single-line takeaway.
Taurine levels decline with age in multiple species; supplementation extended lifespan in mice and improved health markers in middle-aged monkeys. Human data were observational and cross-sectional — not an outcome trial.
Single doses of 1–6 g taurine produced small but statistically significant improvements in endurance performance across 10 studies. Effect size modest and variable.
Pooled analysis of small RCTs showed systolic and diastolic blood pressure reductions of several mmHg, most pronounced in hypertensive populations.
3 g/day taurine for 7 weeks reduced body weight and improved atherogenic index in overweight young adults. Small trial, short duration.